Immatics Announces Full Year 2023 Financial Results and Corporate Update
Interim clinical data update on ACTengine® IMA203 GEN1 (PRAME) in melanoma at RP2D in November 2023: 50% confirmed objec…
Interim clinical data update on ACTengine® IMA203 GEN1 (PRAME) in melanoma at RP2D in November 2023: 50% confirmed objec…
Phase 1/2 clinical trial initiated evaluating Immatics’ second next-generation half-life extended TCR Bispecific program…
ACTengine® IMA203 TCR-T monotherapy against PRAME showed 50% confirmed objective response rate (cORR) at or above target…
Interim clinical update on ACTengine® IMA203 TCR-T monotherapy targeting PRAME demonstrated high confirmed objective res…
Scientific poster presented at the 13th International Newborn Brain Conference Data demonstrate the importance of novel…
ACTengine® patient recruitment remains on track; as of end of July, a total of 27 patients have been treated with IMA201…
Phase 1a data update from clinical ACTengine® programs demonstrated first anti-tumor activity at early phases of dose es…
Tübinger Brancheninvestor SHS geht Minderheitsbeteiligung bei Formulierungs-Spezialist Develco Pharma ein Develco ist s…
Tübingen-based industry investor SHS acquires minority share in formulation specialist Develco Pharma Develco specialize…
ACTengine® IMA200 clinical trial series continues scaling globally; initial analysis for patients in ACTengine® dose esc…